A deeper dive:
There are several categories of things that need research. Just a couple: They look at which cancers express which receptors and how those receptors might change in shape depending on mutations that happen. Similarly, mutated enzyme shapes affect what the cancer cells can and can't do. They look at how proteins might react to interactions with certain types of drugs / immunotherapies. They can also "create" drugs and test them en masse against certain receptors to see which biological shapes/conformations of proteins would interact with, say, a CD20 receptor, so that they can more specifically target with fewer side effects. The amount of work going into it is incredible.
For example, just for one type of lymphoma (DLBCL) there are
dozens of known possible mutated enzymes, and knowing how these fold and what they look like is important in order to simulate how they have their effects and how they might be targeted with new therapies. There are specific drugs being created to target a certain type of DLBCL that relies fairly heavily on the type of work F@H and Rosetta are doing. The issue right now is that R-CHOP chemo is kind of effective, but has a ton of side effects. The end goal of this is to find a specific targeted drug with fewer side effects (something I think
@Markfw can attest is a huge issue) and be more effective against the cancer itself.